Tumor Necrosis Factor (TNF) Inhibitors


Article Author:
Valerie Gerriets


Article Editor:
Karam Khaddour


Editors In Chief:
James Beauchamp
Mark Pellegrini
Nicole Hale-Crutch


Managing Editors:
Orawan Chaigasame
Carrie Smith
Abdul Waheed
Frank Smeeks
Kristina Soman-Faulkner
Benjamin Eovaldi
Radia Jamil
Sobhan Daneshfar
Saad Nazir
William Gossman
Pritesh Sheth
Hassam Zulfiqar
Navid Mahabadi
Steve Bhimji
John Shell
Matthew Varacallo
Ahmad Malik
Mark Pellegrini
James Hughes
Beata Beatty
Hajira Basit
Phillip Hynes


Updated:
2/19/2019 4:53:32 PM

Indications

Tumor necrosis factor (TNF)-alpha inhibitors, including etanercept (E), infliximab (I), adalimumab (A), certolizumab pegol (C) and golimumab (G), are used to treat the following conditions [1][2][3][4]:

FDA-approved Indications (alphabetical list)

  • Ankylosing spondylitis (E, I, A, C, and G)
  • Crohn disease (I, A and C)
  • Hidradenitis suppurativa (A)
  • Juvenile idiopathic arthritis (A)
  • Plaque psoriasis (E, I and A)
  • Polyarticular juvenile idiopathic arthritis (E)
  • Psoriatic arthritis (E, I, A, C, and G)
  • Rheumatoid arthritis (E, I, A, C, and G)
  • Ulcerative colitis (I, A and G)
  • Uveitis (A)

Off-label Indications

  • Graft-vs-host disease
  • Juvenile idiopathic arthritis
  • Pustular psoriasis
  • Pyoderma gangrenosum

Mechanism of Action

The tumor necrosis factor (TNF)-alpha inhibitors, including etanercept, infliximab, adalimumab, certolizumab pegol, and golimumab, all bind to the cytokine TNF and inhibit its interaction with the TNF receptors [5][6]. As a cytokine, TNF is involved with the inflammatory and immune response and can bind to TNF receptor 1 (TNFR1) or TNF receptor 2 (TNFR2) [7].  It occurs in numerous forms, both monomeric and trimeric, as well as soluble and transmembrane. Upon binding, TNF triggers the activation of numerous pathways including the NFkB and MAPK pathways. This leads to the production of numerous inflammatory cytokines and can also lead to TNF-induced apoptotic pathway initiation. Etanercept is a fusion protein of two TNFR2 receptor extracellular domains and the Fc fragment of human IgG1 [8]. It inhibits the binding of both TNF-alpha and TNF-beta to cell surface TNFRs.  Infliximab is a chimeric monoclonal antibody that includes a murine variable region and constant human region [9]. It binds to the soluble and transmembrane forms of TNF-alpha and inhibits the binding of TNF-alpha to TNFR. Adalimumab and golimumab are fully human monoclonal antibodies against TNF-alpha and, like infliximab, these antibodies bind to TNF-alpha and inhibit its binding to TNFR. Certolizumab is a humanized Fab fragment conjugated to polyethylene glycol (PEG).

Administration

Etanercept is administered subcutaneously. The injection sites should be rotated and given at least one inch apart from previous injection sites. 

Infliximab is administered as an infusion. The infusion should occur over a period of 2 hours and should not be co-administered with other agents. Infusion-related reactions are possible, and if necessary, antihistamines, acetaminophen, and corticosteroids can be used to treat these reactions.

Adalimumab is administered by subcutaneous injection. The injection sites should be rotated and away from previous injection sites.

Certolizumab pegol is subcutaneously administered into the thigh or abdomen. 

Golimumab can be administered intravenously (IV) or subcutaneously. Infusions should occur over a period of 30 minutes and should not be co-administered with any other agents. Subcutaneous injections are administered using an autoinjector.

Adverse Effects

The following adverse effects (AEs) were observed in greater than 10% of patients receiving a TNF-alpha inhibitor, including etanercept, infliximab, adalimumab, certolizumab pegol and golimumab [10][11][4][12][8].

Central Nervous System-related AEs: Headache   

Dermatology-related AEs: Skin rash

Gastrointestinal-related AEs: Abdominal pain, nausea, diarrhea

Hematology-related AEs: Anemia

Hepatic-related AEs: Increased serum ALT

Immunology-related AEs: Increased ANA titer (~50%), antibody development

Infection-related AEs: Infection, including serious infection and abscess

Respiratory-related AEs: Upper respiratory tract infections, sinusitis, cough, pharyngitis

Miscellaneous AEs: Infusion-related reaction, injection site reactions

Other serious concerns related to AEs:  Anaphylaxis and hypersensitivity reactions, autoimmune disorders, demyelinating CNS disease, heart failure, aplastic anemia, pancytopenia, reactivation of hepatitis B, leukopenia, neutropenia

US boxed warnings (for all TNF-alpha inhibitors): 

Malignancy:  Malignancies, including lymphoma, have been reported in patients receiving TNF alpha inhibitors. The malignancies arose approximately 30 months (ranging from 1 month to 84 months) after the first dose of the TNF alpha inhibitor and many of the cases were in pediatric and young adult populations. Additionally, cases of hepatosplenic T-cell lymphoma have been reported in the postmarketing period for adolescent males with either ulcerative colitis or Crohn disease. 

Tuberculosis:  Active tuberculosis or the reactivation of latent tuberculosis has been reported in patients receiving TNF-alpha inhibitors. Patients should be evaluated for the presence of tuberculosis before the initiation of therapy with TNF alpha inhibitors and treatment with antimycobacterial therapy should be initiated if latent tuberculosis is found. In cases of reactivation of latent tuberculosis, the reactivation occurs within the first few months of treatment with TNF-alpha inhibitors.

Infection:  Patients receiving treatment with a TNF-alpha inhibitor are at heightened risk of developing serious or fatal infections. This occurred more commonly in patients that are receiving treatment with other immunosuppressive agents including methotrexate and corticosteroids. The types of infections include fungal infections, such as aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis and pneumocystosis, and bacterial and viral infections. In particular, legionellosis and listeriosis have been reported. Patients should be monitored for signs of infection and treatment with TNF-alpha inhibitors should be discontinued if serious infection or sepsis occurs. Empiric antifungal therapy should be considered in patients who are at increased risk of invasive fungal infections.

Contraindications

Etanercept: Do not administer to patients with sepsis.

Infliximab: Do not administer to patients with hypersensitivity to infliximab or murine proteins.

Adalimumab: None listed

Certolizumab pegol: None listed 

Golimumab: None listed

Monitoring

Monitoring of etanercept, infliximab, adalimumab, certolizumab pegol, and golimumab includes latent tuberculosis (TB) screening before initiating treatment and during therapy [12]. The patient should also be monitored for signs of infection before, during and after treatment [13].  Additionally, a CBC with differential and HBV screening should be performed. In certain patients, symptoms of heart failure, malignancy, hypersensitivity reactions, and lupus should be monitored. 

Toxicity

Etanercept: The toxicity profile of etanercept is unknown; long-term human or animal studies have not been conducted. It was not shown to be mutagenic in vitro or in vivo studies.

Infliximab: The toxicity profile of infliximab is unknown. It also is not known if infliximab impairs fertility in humans.

Adalimumab: The toxicity profile of adalimumab is unknown; long-term human or animal studies have not been conducted. It was not shown to be mutagenic in vitro or in vivo studies.

Certolizumab pegol: The toxicity profile of certolizumab is unknown; long-term human or animal studies have not been conducted. It did not impair fertility in an in vivo mouse study.

Golimumab: The toxicity profile of golimumab is unknown; long-term human or animal studies have not been conducted. It did not impair fertility in an in vivo mouse study. 

Enhancing Healthcare Team Outcomes

As with many medications, there must be interprofessional communication when it comes to the dispensing and monitoring of the various TNF alpha inhibitors.  With inflammatory bowel disease and other autoimmune disorders, physicians and pharmacists must be aware of the treatment guidelines when making the decision to treat with TNF alpha inhibitors as opposed to other treatment options [14].  Pharmacists, nurses and physicians must work together to ensure that proper dosing and dispensing protocols are in place and be aware of the possibility of adverse effects [15].  For example, infliximab requires an infusion over a specific period of time, cannot be combined with other medications and there is the possibility of infusion-related reactions.  Therefore, the healthcare team must work together to ensure patient safety, and the use of electronic medical records may be useful in this setting [16].  Additionally, the healthcare team should be aware of the evolving nature of biosimilars as they relate to prescribing TNF alpha inhibitors and keep up-to-date on the available prescribing options [17]


Interested in Participating?

We are looking for contributors to author, edit, and peer review our vast library of review articles and multiple choice questions. In as little as 2-3 hours you can make a significant contribution to your specialty. In return for a small amount of your time, you will receive free access to all content and you will be published as an author or editor in eBooks, apps, online CME/CE activities, and an online Learning Management System for students, teachers, and program directors that allows access to review materials in over 500 specialties.

Improve Content - Become an Author or Editor

This is an academic project designed to provide inexpensive peer-reviewed Apps, eBooks, and very soon an online CME/CE system to help students identify weaknesses and improve knowledge. We would like you to consider being an author or editor. Please click here to learn more. Thank you for you for your interest, the StatPearls Publishing Editorial Team.

Tumor Necrosis Factor (TNF) Inhibitors - Questions

Take a quiz of the questions on this article.

Take Quiz
Which of the following is not an adverse event associated with the use of tumor necrosis factor (TNF) inhibitors?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
Which of the following conclusions is correct in the case of fevers, chills and headaches in a patient on a TNF inhibitor for rheumatoid arthritis?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
Which of the following statements is true about etanercept?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
Which of the following conclusions is correct in the case of fever, chills, and headache in a patient starting a tumor necrosis factor (TNF) inhibitor for rheumatoid arthritis?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
A patient with active rheumatoid arthritis has been started on anti-tumor necrosis factor therapy. Which vaccine should not be administered to this patient?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
A patient with established rheumatoid arthritis and high disease activity level presents to the clinic. The provider starts antitumor necrosis factor inhibitor therapy right away. The patient was never started on a disease-modifying antirheumatic drug. Now after the biological therapy, her disease level still remains high. What should be done at this point?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
A 52-year-old woman with rheumatoid arthritis presented to her physician with worsening symptoms consistent with progressive disease. In addition to NSAID and methotrexate therapy, treatment with a second line agent whose mechanism of action is antagonism of tumor necrosis factor was initiated. Which of the following drugs best describes this agent?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
A 52-year-old woman with rheumatoid arthritis presented to her physician worsening symptoms consistent with progressive disease. In addition to NSAID and methotrexate therapy, treatment with a second line agent which is a chimeric monoclonal antibody against tumor necrosis factor. Which of the following drugs best describes this agent?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up

Tumor Necrosis Factor (TNF) Inhibitors - References

References

New strategies to address the pharmacodynamics and pharmacokinetics of tumor necrosis factor (TNF) inhibitors: A systematic analysis., Meroni PL,Valentini G,Ayala F,Cattaneo A,Valesini G,, Autoimmunity reviews, 2015 Sep     [PubMed]
Efficacy, safety and pharmacokinetics of biosimilars of anti-tumor necrosis factor-α agents in rheumatic diseases; A systematic review and meta-analysis., Komaki Y,Yamada A,Komaki F,Kudaravalli P,Micic D,Ido A,Sakuraba A,, Journal of autoimmunity, 2017 May     [PubMed]
Anti-TNF therapy: safety aspects of taking the risk., Rosenblum H,Amital H,, Autoimmunity reviews, 2011 Jul     [PubMed]
TNF inhibitors in rheumatoid arthritis and spondyloarthritis: Are they the same?, Rubbert-Roth A,Atzeni F,Masala IF,Caporali R,Montecucco C,Sarzi-Puttini P,, Autoimmunity reviews, 2017 Nov 3     [PubMed]
Differentiating the efficacy of the tumor necrosis factor inhibitors., Haraoui B,, Seminars in arthritis and rheumatism, 2005 Apr     [PubMed]
Anti-TNF therapy., Thalayasingam N,Isaacs JD,, Best practice & research. Clinical rheumatology, 2011 Aug     [PubMed]
Mocci G,Marzo M,Papa A,Armuzzi A,Guidi L, Dermatological adverse reactions during anti-TNF treatments: focus on inflammatory bowel disease. Journal of Crohn's     [PubMed]
Cheifetz A,Smedley M,Martin S,Reiter M,Leone G,Mayer L,Plevy S, The incidence and management of infusion reactions to infliximab: a large center experience. The American journal of gastroenterology. 2003 Jun;     [PubMed]
Feldmann M,Maini RN, Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annual review of immunology. 2001;     [PubMed]
Roach DR,Bean AG,Demangel C,France MP,Briscoe H,Britton WJ, TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. Journal of immunology (Baltimore, Md. : 1950). 2002 May 1;     [PubMed]
Gottlieb AB, Tumor necrosis factor blockade: mechanism of action. The journal of investigative dermatology. Symposium proceedings. 2007 May;     [PubMed]
Moreland LW,Schiff MH,Baumgartner SW,Tindall EA,Fleischmann RM,Bulpitt KJ,Weaver AL,Keystone EC,Furst DE,Mease PJ,Ruderman EM,Horwitz DA,Arkfeld DG,Garrison L,Burge DJ,Blosch CM,Lange ML,McDonnell ND,Weinblatt ME, Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Annals of internal medicine. 1999 Mar 16     [PubMed]
Maini R,St Clair EW,Breedveld F,Furst D,Kalden J,Weisman M,Smolen J,Emery P,Harriman G,Feldmann M,Lipsky P, Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet (London, England). 1999 Dec 4     [PubMed]
Clark M,Colombel JF,Feagan BC,Fedorak RN,Hanauer SB,Kamm MA,Mayer L,Regueiro C,Rutgeerts P,Sandborn WJ,Sands BE,Schreiber S,Targan S,Travis S,Vermeire S, American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006. Gastroenterology. 2007 Jul     [PubMed]
    [PubMed]
    [PubMed]
    [PubMed]

Disclaimer

The intent of StatPearls is to provide practice questions and explanations to assist you in identifying and resolving knowledge deficits. These questions and explanations are not intended to be a source of the knowledge base of all of medicine, nor is it intended to be a board or certification review of Pharmacy-Technician (PTCB). The authors or editors do not warrant the information is complete or accurate. The reader is encouraged to verify each answer and explanation in several references. All drug indications and dosages should be verified before administration.

StatPearls offers the most comprehensive database of free multiple-choice questions with explanations and short review chapters ever developed. This system helps physicians, medical students, dentists, nurses, pharmacists, and allied health professionals identify education deficits and learn new concepts. StatPearls is not a board or certification review system for Pharmacy-Technician (PTCB), it is a learning system that you can use to help improve your knowledge base of medicine for life-long learning. StatPearls will help you identify your weaknesses so that when you are ready to study for a board or certification exam in Pharmacy-Technician (PTCB), you will already be prepared.

Our content is updated continuously through a multi-step peer review process that will help you be prepared and review for a thorough knowledge of Pharmacy-Technician (PTCB). When it is time for the Pharmacy-Technician (PTCB) board and certification exam, you will already be ready. Besides online study quizzes, we also publish our peer-reviewed content in eBooks and mobile Apps. We also offer inexpensive CME/CE, so our content can be used to attain education credits while you study Pharmacy-Technician (PTCB).